The incidence of ovarian cancer is ranked third in female genital malignant tumours.
cancer patients were treated with DDP-based chemotherapy, about 15%-25% patients were present primary drug resistance and among them about 80% patients were eventually developed to secondary DDP resistance. [8] [9] [10] [11] Therefore, drug resistance can directly affect the efficacy of chemotherapy and the prognosis of ovarian cancer patients. At present, exploring the mechanism of drug resistance in ovarian cancer and developing new drugresistant reversing agent have become a hot spot in the field of oncology worldwide.
Cyclic adenosine monophosphate (cAMP) could activate protein kinase A (PKA) and cyclic AMP response element-binding protein (CREB), playing important roles in gene regulation, cell migration, cell proliferation, cell apoptosis and mitochondrial homeostasis. [12] [13] [14] Phosphodiesterases (PDEs) are responsible for hydrolyzation of cAMP to its inactive 5′-monophosphate. 15 In recent years, several scholars have begun to explore whether inhibition of PDE4 could play an anti-tumor effect. [16] [17] [18] [19] [20] [21] Our previous study investigated the role of PDE4 inhibitor roflumilast in the treatment of ovarian cancer. 22 After administration with roflumilast, the proliferations of ovarian cancer cell lines OVCAR3
and SKOV3 were significantly inhibited, and the cell apoptosis in those cells were significantly increased. 22 Roflumilast activated the cAMP/PKA/CREB pathway and upregulated the mitochondrial ferritin (FtMt) level in OVCAR3 and SKOV3 cells.
22
Overexpression of FtMt in OVCAR3 and SKOV3 cells induced cell apoptosis and inhibited tumour development. 22 The PKA inhibitor H89 suppressed the expression of FtMt and restored the roflumilast-inhibited cell proliferation and -induced cell apoptosis, indicating the PKA pathway involved in the roflumilast-inhibited cell proliferation and -induced-cell apoptosis. 22 In addition, downregulation of CREB significantly inhibited the expression of FtMt, and levels of PKA activity and phosphorylation of CREB. 22 Those findings suggested that roflumilast promoted cell proliferation and inhibited cell apoptosis in ovarian cancer through upregulation of FtMt via cAMP/PKA/ CREB pathway. DDP is a basic medicine for combined chemotherapy of ovarian cancer and plays an important role in the comprehensive treatment of ovarian cancer. However, the roles of roflumilast in DDP sensitivity and DDP resistance of ovarian cancer cells are still unclear.
In this study, we aimed to study the effect of PDE4 inhibitor roflumilast on the proliferation, apoptosis and cell-cycle progression ovarian cancer cell lines OVCAR3 and SKOV3 cells that were treated with DDP. Then, DDP-resistant ovarian cancer cells including OVCAR3-DDP-R and SKOV3-DDP-R were constructed.
The effect of roflumilast on the proliferation, apoptosis and cell cycle progression of DDP-resistant ovarian cancer cells were investigated. The changes in FtMt expression and cAMP/PKA/ CREB pathway were also investigated. Functional analysis of chemoresistance-related genes will not only help to elucidate the molecular mechanism of chemoresistance in ovarian cancer, but will also help to find new targets for drug screening and prognosis for ovarian cancer treatment.
| MATERIAL AND ME THODS

| Cell culture
This study was performed on two ovarian cancer cell lines, OVCAR3 
| Cell transfection
Cells were transfected with shRNA pGenesil-CREB or shRNA negative control (NC) in 12-well plates for the indicated time.
The shRNA vectors were synthesized by GenePharma, Shanghai, China. Transfection was performed with 1 ng/mL shRNA, using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
| Roflumilast and H89 treatments
Cells were treated with the PDE4 inhibitor roflumilast (15 μM) (Sigma, MO, USA) and/or the PKA inhibitor H89 (10 μM) (Sigma, St.
Louis, MO, USA) for the indicated times and at the indicated concentrations. Cell proliferation, apoptosis, cell cycle, and tumour formation assays were then performed.
| Cell proliferation assays
After treatment, cell proliferation was detected by cell counting kit-8 (CCK-8; Kumamoto, Japan), EDU staining (Roche, USA), and colon formation assays. For the CCK-8 assay, cells were seeded in 96-well plates. The CCK-8 test solution was added 4 h before the end of treatment. The absorbance was measured at 450 nm using a microplate reader. For the EDU assay, cells were fixed with 4% paraformaldehyde (PFA) for 30 min and then stained with EDU and DAPI.
The images were captured with FV10i fluorescence microscopy (Olympus, Shinjuku-ku, Tokyo, Japan). For colon formation assay, cells were seeded in 6-well plates at 500 cells/well and exposed to the indicated treatment. After 13 days, cells were fixed with 4% PFA and stained with 0.1% crystal violet.
| Flow cytometry assay
After treatment, cell apoptosis and cell cycle were detected by flow cytometry (BD FACS Calibur, USA). To assess apoptosis, 
| Hoechst staining assay
After treatment, cells were fixed with 4% PFA, and stained with 0.1 μg/mL Hoechst 33342 (Sigma, MO, USA). The changes in nuclear morphology were visualized, using FV10i fluorescence microscopy (Olympus, Shinjuku-ku, Tokyo, Japan) with a 365-nm filter.
| ELISA detection of cAMP and PKA activities
After treatment, the levels of cAMP and PKA activities were detected, using competitive ELISA kits (Invitrogen, Carlsbad, CA, USA). The cAMP ELISA kit (Cat. EMSCAMPL) and PKA ELISA kit (Cat. EIAPKA)
were used in this study according to the manufacturer's instructions.
| RNA isolation and real time-quantitative PCR (RT-qPCR)
After treatment, total RNAs from cells were isolated using Trizol reagent (Invitrogen) according to the standard protocol. RT-qPCR was performed using the SYBR Premix Ex Taq TM (Takara, Shiga, Japan)
and Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The primers used in this study are listed in Table 1 . The tests were performed in triplicate. Gene expression was normalized to GAPDH expression, and calculated using the method of 2 −ΔΔCt .
| Immunofluorescence
After treatments, cells were fixed with 4% PFA in PBS for 15 min and permeabilized with 100% methanol for 10 min at −20°C. After blocking with 2% goat serum for 60 min, cells were incubated with the primary antibody against FtMt (#ab66111, Abcam, Cambridge, Massachusetts, USA) overnight at 4°C. After incubation with fluorochrome-conjugated secondary antibody for 1-2 h at room temperature in the dark, the nucleus was stained using DAPI. The cells were visualized by LSM 510. 
| Xenograft model
The animal experiments were approved by the Animal Care and Use
Committee of Nanfang Hospital, Southern Medical University. A total of 2 × 10 6 SKOV3 or SKOV3-DDP-R cells were injected subcutaneously into 6-week-old male BALB/c nude mice. Tumour diameters were measured using a digital caliper and calculated using the formula: volume = π/6(width) 2 × length. When tumours were grown to 100-150 mm 3 , the mice were randomly divided into control, DDP, and DDP + roflumilast groups (for SKOV3), and control and roflumilast groups (for SKOV3-DDP-R). For roflumilast and/or DDP treatment, 5 mg/kg roflumilast and/or 2 mg/kg DDP was injected intraperitoneally (i.p.) into mice five times, 3 days apart. After the last treatment, the mice were sacrificed and the xenograft tumours were harvested for subsequent experiments.
| Immunohistochemistry
The tumour tissues were paraffin embedded and sectioned to 2-μm thickness. After heating at 60°C for 30 min, the sections were deparaffinized with xylene for 5 min and rehydrated in graded concentrations of ethanol. Antigen retrieval was performed and then the slides were Francisco, California) and DAB chromogen EnVision Detection System kit (DAKO, Produktionsvej, Glostrup, Denmark) were used for detection. Hematoxylin was used for nuclear staining.
| Western blotting
Proteins were extracted from cells or tissues using RIPA lysis buffer and overnight at 4°C. The membranes were then incubated with HRPconjugated secondary antibody (#BS12478, #BS13278, Bioworld, China) for 1 h at room temperature, and the blots were visualized, using the ECL-Plus reagent (Millipore, Billerica, MA, USA).
| Statistical analysis
Data were performed in triplicate and presented as mean ± standard deviation. The analysis was performed with spss 16.0 using student t tests for two groups, and one-way ANOVA with SNK for multiple group comparisons. P < .05 was considered to be statistically significant.
| RE SULTS
| Roflumilast increased the DDP sensitivity of ovarian cancer cells
In both OVCAR3 ( Figure 1A 
GAPDH R ATGGCATGGACTGTGGTCAT Lnc-CCAT1 F CCTACGCATACCTCTGCTTCT 138
Lnc-CCAT1 R GATTGCTCCTGTTTCCCTTT decreased to 1.61 and 1.315 μM, respectively. DDP increased the apoptosis rates in OVCAR3 ( Figure 1C ) and SKOV3 ( Figure 1D ) cells.
After administration of roflumilast + DDP, the apoptosis rates were significantly increased, compared with DDP. Hoechst assay showed that roflumilast significantly increased apoptosis in OVCAR3 and SKOV3 cells in presence of DDP ( Figure 1E ,F). The cell cycle was then assessed, and the results showed that roflumilast increased the DDPinduced G0/G1 arrest in OVCAR3 and SKOV3 cells ( Figure 1G ,H).
| Roflumilast induced expression of FtMt and increased the activity of cAMP/PKA/CREB in ovarian cancer cells
We found that roflumilast significantly increased the DDP-induced expression of FtMt, as assessed by levels of both mRNA (Figure 2A,B) and protein ( Figure 2C -F) in OVCAR3 and SKOV3 cells.
Given that PDE4 could hydrolyse and inactivate cAMP, it was expected that roflumilast, an inhibitor of PDE4, elevated the level of cAMP in OVCAR3 cells ( Figure 3A) . Also, roflumilast increased the activity of PKA, a cAMP effector in OVCAR3 cells ( Figure 3B ).
Moreover, roflumilast induced the phosphorylation of CREB in both OVCAR3 ( Figure 3C ) and SKOV3 cells ( Figure 3D ). Figure 10E,F) . In addition, the phosphorylation of CREB was significantly increased by roflumilast in OVCAR3-DDP-R and SKOV3-DDP-R cells ( Figure 10G ). Figures 12H,I ). Downregulation of CREB inhibited roflumilastinduced phosphorylation of CREB ( Figure 12I ).
| H89 inhibited roflumilast-mediated increase in
| Roflumilast inhibited the growth and induced the expression of FtMt and phosphorylation of CREB in a DDP-resistant ovarian cancer cell xenograft model
The effects of roflumilast on DDP resistance in ovarian cancer cells was investigated in vivo. SKOV3-DDP-R xenograft models were established and treated with roflumilast (5 mg/kg). Roflumilast 
| D ISCUSS I ON
Ovarian cancer is one of the malignant tumours of the female reproductive system. Its incidence has risen in recent years.
1,2
Ovarian cancer is a highly lethal malignancy that is prone to blood and lymph node metastasis and local infiltration and easily develops resistance to chemotherapeutic drugs. The prognosis for ovarian cancer patients is poor, with a 5-year survival rate of only 25%-30%. [3] [4] [5] The mechanism of resistance to chemotherapeutic drugs in ovarian cancer has become a hot area of research in recent years. 6, 7 Roflumilast is a PDE4 inhibitor that has been shown to enhance glucocorticoid-mediated apoptosis via upregulation of mRNA levels of glucocorticoid receptor in B cell chronic lymphocytic leukaemia cells. 24 However, in breast cancer cells, PDE4 inhibitor suppresses cell migration with little effect on cell proliferation. 25 In non-small cell lung cancer, roflumilast is used as an orally administered drug for the treatment of inflammatory conditions of the lungs. The combination of DDP with roflumilast has been shown to induce satisfactory apoptosis in lung cancer. 21 It was implicated that the anti-tumour effect of roflumilast might depend on cell type. Consistent with findings in non-small-cell lung cancer, roflumilast induced cell apoptosis and inhibited proliferation of ovarian cancer cells via upregulation of FtMt. 22 It was suggested that roflumilast could be used to treat ovarian cancer. However, roflumilast has many side effects in lung cancer treatment. Although the side effects in ovary cancer are unclear, alterations in the structure of the drug or improvement in synthetic analogues may decrease side effects.
26
Upregulation of FtMt has been hypothesized as a possible mechanism for roflumilast-induced cell apoptosis. In this study, we found that roflumilast induced cell apoptosis and inhibited proliferation of OVC cells via upregulation of FtMt. FtMt is an H-ferritin-like protein in mitochondria. It is encoded by an intronless gene mapped to chromosome 5q23.1 and involved in modulating cellular iron metabolism and oxidative stress. [27] [28] [29] [30] FtMt dysregulation has been reported in erythroid cells from patients with sideroblastic anaemia.
31
FtMt was upregulated after ABCB7 silencing in normal progenitors during erythroid differentiation. 32 FtMt was decreased in nervous system tumour tissues, including neuroblastoma and neurospongioma, 33 and overexpression of FtMt suppresses the proliferation of neuroblastoma cells. 33 In this study, roflumilast enhanced cisplatin 
37
This study showed that roflumilast significantly enhanced cAMP levels in DDP-sensitive cells and in DDP-resistant cells. The increased levels of cAMP could activate cAMP-dependent PKA, which phosphorylates many target proteins including CREB. 35, 36 However, the relationship between FtMt and cAMP is unclear.
The level of CREB expression in ovarian cancer is related to tumour stage and prognosis of the ovarian cancer patient. 38 With an increase in staging, CREB expression increased significantly, indicating that CREB plays an important role in the progress of ovarian cancer. 38 High CREB expression is associated with poor prognosis. 39 In mucinous ovarian cancer, the most common mutation is in K-ras, and activating mutant K-ras will lead to CREB phosphorylation, resulting 
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